BiPER Therapeutics
www.biper-tx.comBiPER Therapeutics is developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.
Read more
BiPER Therapeutics is developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.
Read more
Country
City (Headquarters)
Strasbourg
Industry
Employees
1-10
Founded
2021
Social
Employees statistics
View all employeesPotential Decision Makers
Co - Founder Biper Therapeutics
Email ****** @****.comPhone (***) ****-****Co - Founder and Chief Executive Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(5)
Reach decision makers at BiPER Therapeutics
Free credits every month!
BiPER Therapeutics FAQ
Strasbourg, France
Biotechnology Research
